BioSpace News Archive

Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, reported financial results for the first quarter ended March 31, 2020 and provided a review of recent business and clinical highlights.

KOST 103.5’s on-air personality Ellen K and Los Angeles Dodgers third baseman Justin Turner and his wife Kourtney serve as honorary hosts for the family-friendly event supporting CHLA’s everyday heroes

AngioDynamics, Inc. announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will participate in a virtual fireside chat at the UBS Virtual Global Healthcare Conference at 9:10 a.m.

Dynavax Technologies Corporation, a biopharmaceutical company focused on developing and commercializing novel vaccines, reported financial results for the first quarter of 2020.

CytomX Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® therapeutic technology platform, reported first quarter 2020 financial results and provides a business update.

TYMLOS® U.S. net sales of $48 million, with 61% year over year growth Our three Phase 3 studies continue to advance amid slowdown in recruitment due to COVID-19 pandemic. Anticipated data read-outs remain on track for second half of 2021 Due to anticipated impact of pandemic, 2020 TYMLOS U.S. net revenue guidance mid-point reduced by 10% to between $190M and $220M. Full year cash burn is expected to be below $100M Kelly Martin appointed President and Chief Executive Officer as of Apr

Conference call to discuss financial and operational results scheduled for Friday, May 8 at 8:30 a.m. U.S. Eastern Time

NURTEC™ ODT (rimegepant) received FDA-approval for acute treatment of migraine on February 27, 2020 and Biohaven reports net revenues of $1.2M in March 2020 after launch in U.S. Pharmacies

Edwards Lifesciences Corporation, the global leader in patient-focused innovations for structural heart disease and critical care monitoring, announced updates from its annual meeting, in which Edwards’ stockholders voted with the board’s recommendations on all proxy proposals.

Cash and investments in marketable securities at March 31, 2020 were approximately $1.5 billion as compared to $1.6 billion at December 31, 2019.